Hazard of Recurrence among Women after Primary Breast Cancer Treatment—A 10-Year Follow-up Using Data from SEER-Medicare
暂无分享,去创建一个
Dejian Lai | Lee Cheng | Hui Zhao | Sharon H. Giordano | T. Buchholz | D. Lai | S. Giordano | P. Rowan | A. Kapadia | Michael D. Swartz | Asha S. Kapadia | Paul J. Rowan | Thomas A. Buchholz | Hui Zhao | Lee Cheng | M. Swartz
[1] V T Farewell,et al. The analysis of failure times in the presence of competing risks. , 1978, Biometrics.
[2] J. Jollis,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.
[3] Melissa Bondy,et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. , 2008, Journal of the National Cancer Institute.
[4] Thomas J. Smith,et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Sanghera,et al. A study of medical intervention in routine breast cancer follow-up. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).
[6] L. Tafra,et al. American Society of Clinical Oncology‐recommended surveillance and physician specialty among long‐term breast cancer survivors , 2010, Cancer.
[7] R. Demicheli,et al. Recurrence and mortality according to Estrogen Receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast , 2010, BMC Cancer.
[8] S. P. Wright,et al. Adjusted P-values for simultaneous inference , 1992 .
[9] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[10] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[11] J. Lin,et al. Prevention, Screening, and Surveillance Care for Breast Cancer Survivors Compared With Controls: Changes from 1998 to 2002 , 2010 .
[12] T. Oliver,et al. Follow-up for women after treatment for cervical cancer. , 2010, Current oncology.
[13] Kathleen Lang,et al. Identifying Cancer Relapse Using SEER-Medicare Data , 2002, Medical care.
[14] Vanja Dukic,et al. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer , 2009, Breast Cancer Research and Treatment.
[15] Rosalba Miceli,et al. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy , 2005, Breast Cancer Research and Treatment.
[16] I. Langner. Survival Analysis: Techniques for Censored and Truncated Data , 2006 .
[17] J. Dignam. Hazard of Recurrence among Women after Primary Breast Cancer Treatment–A 10-Year Follow-up Using Data from SEER-Medicare , 2013 .
[18] R. Gray,et al. Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Earle,et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Satagopan,et al. A note on competing risks in survival data analysis , 2004, British Journal of Cancer.
[21] G. Kerr,et al. Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience , 2007, British Journal of Cancer.
[22] S. Hilsenbeck,et al. Hazard rates of recurrence following diagnosis of primary breast cancer , 2004, Breast Cancer Research and Treatment.
[23] Z. Hall. Cancer , 1906, The Hospital.
[24] D J Ferguson,et al. Dormancy of mammary carcinoma after mastectomy. , 1999, Journal of the National Cancer Institute.
[25] R. Epstein,et al. Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study , 1997, BMJ.
[26] V. A. Epanechnikov. Non-Parametric Estimation of a Multivariate Probability Density , 1969 .
[27] S. Stenning,et al. Evidence to support a change in follow-up policy for patients with breast cancer: time to first relapse and hazard rate analysis. , 1999, Clinical oncology (Royal College of Radiologists (Great Britain)).
[28] R. Demicheli,et al. Recurrence dynamics does not depend on the recurrence site , 2008, Breast Cancer Research.
[29] Elia Biganzoli,et al. Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: Different mortality but similar recurrence , 2010, Cancer science.
[30] O. Aalen,et al. Understanding the shape of the hazard rate: A proce ss point of view , 2002 .
[31] P. Jacobsen,et al. Clinical practice guidelines for the psychosocial care of cancer survivors , 2009, Cancer.